Sec. 209. Reports and studies on medication treatments for opioid use disorder
347 words·~2 min read·
/bill/118/s/3106/is/section-209A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
Not later than 2 years after the date of enactment of this Act, the Director of the National Institutes of Health shall— submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives a report on ongoing and new clinical studies conducted or funded by the National Institutes of Health on the access to, safety of, and efficacy of methadone treatment for opioid use disorder in accredited and certified opioid treatment programs and in other programs or settings; and brief the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives on— interim results from the studies described in paragraph (1); and any barriers that may prevent adequate and timely enrollment of patients in any new clinical study described in paragraph (1).
The Secretary of Health and Human Services, acting through the Assistant Secretary for Mental Health and Substance Use, shall— study— the early impact on access to medication treatment for opioid use disorder and opioid-related overdose deaths through buprenorphine prescribing pursuant to section 303(g) of the Controlled Substances Act ( 21 U.S.C. 823(g) ), as amended by section 1262 of title I of division FF of the Mental Health and Well-Being Act of 2022; the prevalence of patients with opioid use disorder, in each Substate region, as defined by the National Survey on Drug Use and Health of the Substance Abuse and Mental Health Services Administration; and a survey of retail pharmacies nationwide, disaggregated by State, to determine which pharmacies serve as methadone dispensing units for opioid treatment programs; and submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives— not later than 3 years after the date of enactment of this Act, an initial report on the study under paragraph (1); and not later than 4 years after the date of enactment of this Act, a final report on the study under paragraph (1).
Connectionstraces to 1
Traces to 1 document
U.S. Code
Citation graph
cites case law
Sec. 209
Reports and studies on medication treatments for opioid use disorder
Cites 1Cited by 0 across 0 sources